Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Target Price at $78.88

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $78.88.

ANIP has been the topic of several research analyst reports. HC Wainwright assumed coverage on ANI Pharmaceuticals in a research report on Thursday, July 10th. They issued a "buy" rating and a $84.00 price target on the stock. Guggenheim reaffirmed a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Wall Street Zen cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. Finally, Truist Financial boosted their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research report on Monday, April 21st.

ANI Pharmaceuticals Stock Down 1.6%

Shares of NASDAQ:ANIP traded down $1.08 during midday trading on Tuesday, hitting $66.97. 100,041 shares of the stock were exchanged, compared to its average volume of 320,292. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.98 and a current ratio of 2.66. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $77.00. The business's fifty day simple moving average is $62.88 and its two-hundred day simple moving average is $62.58. The company has a market capitalization of $1.45 billion, a PE ratio of -52.73 and a beta of 0.57.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.33. The business had revenue of $197.12 million during the quarter, compared to analyst estimates of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. ANI Pharmaceuticals's quarterly revenue was up 43.4% compared to the same quarter last year. During the same period last year, the company earned $0.82 earnings per share. As a group, research analysts predict that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $64.88, for a total value of $25,952.00. Following the completion of the transaction, the vice president owned 78,945 shares of the company's stock, valued at $5,121,951.60. The trade was a 0.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christopher Mutz sold 4,000 shares of the business's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the transaction, the insider directly owned 107,317 shares of the company's stock, valued at $6,487,312.65. This trade represents a 3.59% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,681 shares of company stock worth $345,222. Insiders own 11.10% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. State of Alaska Department of Revenue lifted its stake in ANI Pharmaceuticals by 10.0% in the 2nd quarter. State of Alaska Department of Revenue now owns 10,116 shares of the specialty pharmaceutical company's stock valued at $659,000 after acquiring an additional 920 shares in the last quarter. Voya Investment Management LLC lifted its stake in ANI Pharmaceuticals by 12.0% in the 1st quarter. Voya Investment Management LLC now owns 8,934 shares of the specialty pharmaceutical company's stock valued at $598,000 after acquiring an additional 957 shares in the last quarter. Jane Street Group LLC bought a new stake in ANI Pharmaceuticals in the 1st quarter valued at approximately $2,706,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock valued at $3,235,000 after acquiring an additional 423 shares in the last quarter. Finally, Woodline Partners LP acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth about $11,144,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.